Skip to main content
. 2013 Apr 23;8(4):e62183. doi: 10.1371/journal.pone.0062183

Figure 2. Proportion of Reported Incremental Cost-Effectiveness Ratios Below Reported Willingness-to-Pay Threshold.

Figure 2

*Includes results of dabigatran compared to “real-world prescribing”, “trial-like” warfarin control and genotype-guided warfarin †Includes results of dabigatran compared to “trial-like” warfarin control and genotype-guided warfarin.